This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna (CI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of +0.84% and +7.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Q2 Earnings Miss Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of -0.36% and +5.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
The Joint Misses Q1 Earnings Estimates on Rising Expenses
by Zacks Equity Research
JYNT expects to open 30-40 franchised clinics in 2025, down from 57 last year.
The Joint Corp. (JYNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of -50% and 2.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in The Joint (JYNT) Stock?
by Zacks Equity Research
Investors need to pay close attention to The Joint (JYNT) stock based on the movements in the options market lately.
Cigna (CI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 5.48% and 7.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -2.22% and 0.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 16.03% and 0.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) Stock Jumps 10.0%: Will It Continue to Soar?
by Zacks Equity Research
The Joint (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Joint Corp. (JYNT) Matches Q4 Earnings Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of 0% and 50.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Joint Gears Up for Q4 Earnings: Here's What to Expect
by Zacks Equity Research
JYNT's fourth-quarter results are likely to reflect higher Royalty fees, Software fees and Advertising fund revenues.
Select Medical (SEM) Lags Q4 Earnings Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -5.26% and 1.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 4.42% and 1.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
JYNT's Q3 Earnings Meet Estimates Amid Higher Costs, Shares Dip 3%
by Zacks Equity Research
The Joint's Q3 results reflect higher general and administrative costs. Revenues benefit from strong royalty fees and advertising revenues.
The Joint Corp. (JYNT) Q3 Earnings Match Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of 0% and 5.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.02% and 6.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 16.55% and 10.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth Group (UNH) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 1.85% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) Forays Into San Francisco Chiropractic Market
by Zacks Equity Research
This year, The Joint (JYNT) intends to open 60-70 new franchised clinics compared with 104 opened last year.
The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of -500% and 2.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.67% and 3.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine
by Zacks Equity Research
Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.
Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues
by Zacks Equity Research
Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.
Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio
by Zacks Equity Research
Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.
Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY
by Zacks Equity Research
Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.